Nebula Research & Development LLC Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Nebula Research & Development LLC raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 140.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,129 shares of the medical equipment provider's stock after buying an additional 9,434 shares during the period. Nebula Research & Development LLC's holdings in Hologic were worth $1,163,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in HOLX. Brooklyn Investment Group lifted its position in Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after purchasing an additional 145 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the period. Trivant Custom Portfolio Group LLC raised its stake in Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock worth $602,000 after acquiring an additional 169 shares during the period. UMB Bank n.a. lifted its holdings in Hologic by 4.1% during the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after purchasing an additional 188 shares in the last quarter. Finally, Capital Investment Counsel Inc boosted its position in shares of Hologic by 3.6% in the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock worth $413,000 after purchasing an additional 200 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

Shares of HOLX stock opened at $58.02 on Friday. Hologic, Inc. has a 12-month low of $55.89 and a 12-month high of $84.67. The business's fifty day simple moving average is $61.02 and its 200-day simple moving average is $70.00. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $13.02 billion, a PE ratio of 18.30, a PEG ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of analyst reports. Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Morgan Stanley cut their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Citigroup dropped their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada dropped their price objective on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Finally, Argus cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.